ArticleScientific reports2025
Pharmacological and toxicological effects of Jiangfangbaoxin and determination of its components in the blood of spontaneously hypertensive rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oleanolic acid cubic liquid crystal nanoparticle-based thermosensitive gel attenuates knee osteoarthritis symptoms in rats.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Jiangfangbaoxin (JFBX) has been used to attenuate essential hypertension (EH) for over 20 years. Here, we aimed to examine the blood composition and toxicological effects of JFBX using 40 and 10 male age-matched spontaneously hypertensive rats (SHRs) and Wistar-Kyoto, respectively. After 12 weeks of intervention, blood pressure and left ventricular hypertrophy were measured. Subsequently, their organs were harvested for pathological examination. Ultra-high-performance liquid chromate- graphy with quadrupole time-of-flight mass spectrometry was used to explore the components of JFBX in blood. Low and high-doses of JFBX attenuated both systolic and diastolic blood pressure in the SHRs. The high- and low-dose JFBX groups showed significantly reduced endothelin-1 and increased nitric oxide levels. The myocardial tissue levels of tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 in the JFBX-high-dose group were significantly decreased. Furthermore, superoxide dismutase and malonaldehyde levels significantly increased and decreased, respectively. The toxicological results showed that JFBX did not cause particularly severe side effects when administered after 12 weeks. In total, 87 precursor compounds, including alkaloids, iridoid glycosides, flavonoids, siterpenoids, volatile components, and organic phenols/acids, were detected in the blood. JFBX attenuated EH. No serious organ damage was observed after 12 weeks of oral administration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.